id: extended_release_naltrexone_access_to_alcohol_use_disorder_recovery_outcomes
name: Extended-Release Naltrexone (XR-NTX) Access â†’ Alcohol Use Disorder Recovery
  Outcomes
from_node:
  node_id: extended_release_naltrexone_access
  node_name: Extended-Release Naltrexone (XR-NTX) Access
to_node:
  node_id: alcohol_use_disorder_recovery_outcomes
  node_name: Alcohol Use Disorder Recovery Outcomes
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: XR-NTX provides sustained opioid receptor antagonism over 30 days, eliminating
  daily medication adherence barriers'
- 'Step 2: Extended medication coverage reduces alcohol cravings and reinforcing effects
  of alcohol consumption'
- 'Step 3: Reduced craving and alcohol reinforcement enables sustained abstinence
  and engagement in recovery activities'
- 'Step 4: Improved abstinence supports composite recovery outcomes including self-help
  participation, employment, and reduced arrests'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: Paul Crits-Christoph et al. 2016. "A Naturalistic Evaluation of
    Extended-Release Naltrexone in Clinical Practice in Missouri.." *Journal of substance
    abuse treatment*. https://doi.org/10.1016/j.jsat.2016.07.014
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:06.691129'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: medication_formulation
  direction: strengthens
  strength: strong
  description: Extended-release formulation superior to oral naltrexone, likely due
    to improved adherence and sustained pharmacological effect
